Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Domvanalimab (Primary) ; Zimberelimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 05 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Nov 2024.
- 29 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Nov 2024.
- 18 Apr 2023 Planned End Date changed from 1 Aug 2023 to 1 Feb 2024.